Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Celgene Corp. will get another chance to argue one of its patent claims related to avoiding side effects caused by cancer drugs is valid ( Coalition for Affordable Drugs VI LLC v. Celgene Corp. , P.T.A.B., No. IPR2015-01096, 9/8/17 ).
The Patent Trial and Appeal Board said the New Jersey-based company was entitled to a rehearing on whether one of its patent claims related to drug delivery methods was obvious. Dallas hedge-fund manager Kyle Bass’s Coalition for Affordable Drugs had asked the U.S. Patent and Trademark Office’s board to review the Celgene patent, which relates to Celgene’s cancer drugs Pomalyst (pomalidomide) and Revlimid (lenalidomide).
The board’s decision means Celgene will have the opportunity to overturn one part of the PTAB’s October 2016 decision finding its U.S. Patent No. 6,315,720 invalid.
Since 2015, Bass has filed a total of 37 petitions challenging several drug companies’ patents before the PTAB, mostly through the Coalition for Affordable Drugs. Bass, who claimed many drug patents had been improperly granted and unfairly protected drug companies’ monopoly prices on drugs, has had mixed success.
The PTAB agreed to review 21 of the petitions filed by Bass. Out of those 21 reviews, the PTAB issued final written decisions in 19 of the challenges, ruling for Bass in 10 decisions.
On Celgene’s ‘720 patent, Administrative Patent Judge Grace Karaffa Obermann granted Celgene’s petition for a rehearing on one of the claims in the patent because the coalition didn’t prove the claim more likely than not was unpatentable for obviousness. That claim covers requiring diagnostic genetic testing information be obtained from patients for diagnosis and treatment to make sure the drugs aren’t given to patients likely to suffer adverse side effects from the drugs.
Obermann left intact the rest of the board’s 2016 decision, in which the PTAB found multiple other claims of the ‘720 patent weren’t patentable. The ‘720 patent covers methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known as, or suspected of, being caused by the drug.
Michael P. Tierney, vice chief administrative patent judge, and Tina E. Hulse, administrative patent judge, also heard argument in the case.
Bloomberg BNA contacted the coalition and Celgene for comment but no one was available to respond.
Skiermont Puckett LLP represented the Coalition for Affordable Drugs.
Quinn Emanuel Urquhart & Sullivan LLP and Jones Day represented Celgene.
To contact the reporter on this story: Dana A. Elfin in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Randy Kubetin at RKubetin@bna.com
The PTAB's final written decision is available at http://src.bna.com/sso.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)